Form 4: Recursion Pharmaceuticals Director Dean Y. Li Acquires Shares Under Compensation Policy

Director Dean Y. Li acquired 1,925 shares of Recursion Pharmaceuticals' Class A Common Stock on October 1, 2024, under the company's Outside Director Compensation Policy.

Summary

• On October 1, 2024, Dean Y. Li, a director of Recursion Pharmaceuticals, acquired 1,925 shares of Class A Common Stock.
• The acquisition was made under the Issuer's Outside Director Compensation Policy.
• Following the transaction, Dean Y. Li directly owns 75,703 shares.
• Dean Y. Li also indirectly owns 1,422,048 shares through the Dean Li and Ruth Li Revocable Trust, 1,269,796 shares through the Dean Y. Li GRAT, and 421,000 shares through the Dean Y. Li 2021 Family Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a routine transaction related to director compensation. There is no indication of positive or negative implications for the company's performance.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.

Industry Context

This filing is a routine disclosure related to insider transactions and is typical for publicly traded companies. It provides transparency into the ownership changes of company insiders.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment as it indicates director's confidence in the company.

Key Dates